Ronald Levy
Developed the first antibody treatment for cancer, rituximab, and still works on training the immune system against lymphoma.
Oncologist whose anti-idiotype and anti-CD20 antibody work led to rituximab, the first approved cancer antibody. Current work tests in situ vaccination with TLR agonists and anti-OX40 in low-grade lymphoma.
| Title | Journal | Year |
|---|---|---|
| Eradication of spontaneous malignancy by local immunotherapy | Science Translational Medicine | 2018 |
| Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody | New England Journal of Medicine | 1982 |
Pages like this
not linked directly; found by shared links- PersonChristopher R. Flowers
Shares CD20, Diffuse large B-cell lymphoma.
- IdeaDrag cancer's surface and secreted proteins to the cell's recycling bin
Shares Stanford Health Care / Stanford Cancer Institute, Monoclonal antibodies.
- PersonIrving L. Weissman
Shares Stanford Health Care / Stanford Cancer Institute, Diffuse large B-cell lymphoma.
- PersonAsh A. Alizadeh
Shares Stanford Health Care / Stanford Cancer Institute, Diffuse large B-cell lymphoma.
- CompanyMorphoSys (Novartis)
Shares Monoclonal antibodies, Diffuse large B-cell lymphoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares CD20, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Monoclonal antibodies, Diffuse large B-cell lymphoma.
- ProductOdronextamab
Shares CD20, Diffuse large B-cell lymphoma.